DURHAM, N.C. — A team of physicians, neuroscientists and engineers at Duke University has demonstrated two new strategies that use deep brain stimulation to improve the symptoms of Parkinson’s disease. By simultaneously targeting two key brain structures and using a novel self-adjusting device, the team showed that they can efficiently...
Latest News
PTC Therapeutics’ Upstaza, a gene therapy for an ultra-rare genetic disorder and the first to be directly infused in the brain, is one step closer to reaching patients in the U.K. The National Institute for Health and Care Excellence (NICE) has recommended the therapy to treat patients with aromatic L-amino acid...
SAN DIEGO – Engrail Therapeutics™ (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies and The Texas A&M University System (TAMUS), today announced that they have entered into a license agreement which grants Engrail worldwide exclusive rights to intellectual property around the use...
WILMINGTON, Del. – AstraZeneca Pharmaceuticals LP and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or...
TOKYO & MUNICH & BASKING RIDGE, N.J. – Detailed primary results from the positive, pivotal DESTINY-Lung01 phase 2 trial of ENHERTU® (trastuzumab deruxtecan), the Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca HER2 directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously-treated patients with...
Chapel Hill, NC – Throughout the day and night, cerebrospinal fluid (CSF) pulses through small fluid-filled channels surrounding blood vessels in the brain, called perivascular spaces, to flush out neuroinflammation and other neurological waste. A disruption to this vital process can lead to neurological dysfunction, cognitive decline, or developmental delays....
Employing “electronic nose” (eNose) technology early during treatment can accurately identify patients with advanced non-small cell lung cancer (NSCLC) who respond to immunotherapy, according to research published in Lung Cancer. The technology can allow for noninvasive, low-cost identification of responders early on, which could save patients from ineffective treatment, “thereby preventing...
PARIS – ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a...
PARIS – ENTEROME SA, a clinical stage biopharmaceutical company developing novel therapeutics based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, is pleased to announce the appointment of Anne Dagallier, PhD, as Chief Business Officer (CBO). Dr Dagallier brings over 22 years of...
BOULDER, Colo. – Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable...